Cao et al.
Three COVID-19 patients in China were treated with high-dose IVIg at the onset of respiratory distress and showed satisfactory clinical and radiographic recovery, suggesting that IVIg may be an effective treatment option.
Zhou et al.
After short-term treatment with combination low-dose corticosteroid and immunoglobulin, ten COVID-19 patients in Changsa, Hunan province, China, showed that their lymphocyte count, oxygenation index, and pulmonary lesions were significantly improved. In this study, short-term moderate-dose corticosteroid plus immunoglobulin reduced the continued deterioration of COVID-19 patients who failed to respond to low-dose therapy.
Xie et al.
Initiation of IVIg as adjuvant treatment for COVID-19 pneumonia within 48 hours of admission to hospital was demonstrated to reduce use of mechanical ventilation, length of ICU and hospital stay, and 28-day mortality in 58 cases of severe COVID-19 in the Wuhan Third Hospital in China from January-February 2020.
Shao et al.
174 critically ill, adult COVID-19 patients from multiple treatment centers in China were treated with high-dose IVIg. The study found that early administration (≤ 7 days) of IVIg can improve the prognosis of critical patients with COVID-19. The study also provides important information on the clinical application of IVIg in treatment of COVID-19 infection, including patient selection, administration timing, and dosage.
Mohtadi et al.
Five severely ill COVID-19 patients in whom standard treatments failed were administrated with IVIG which prevented the deterioration of clinical symptoms. All the patients were treated with high-dose IVIG (0.3-0.5 g/kg) for 5 consecutive days so that no patient would receive lower than 25 g of the drug. All the patients showed a desirable therapeutic response and were discharged from the hospital with a stable clinical condition after being recovered.
Jones et al.
A 6-month old infant diagnosed with classic Kawasaki disease who tested positive for COVID-19 was successfully treated with IVIg and high-dose aspirin to resolve fever and minimal respiratory symptoms.
Feldstein et al.
186 juvenile (<21 years of age) patients with Multisystem inflammatory Syndrome (MIS-C) were studied to understand its epidemiology and clinical course in children and its temporal association with COVID-19. Treatment with immunomodulating therapies was common. As of May 20, 2020, a total of 130 patients (70%) had been discharged alive, 52 (28%) were still hospitalized, and 4 (2%) had died. The study concludes that MIS-C associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents
Dufort et al.
The emergence of Multisystem Inflammatory Syndrome in children (MIS-C) in New York State coincided with widespread SARS-CoV-2 transmission. The New York State Department of Health (NYSDOH) established active, statewide surveillance to describe hospitalized patients with the syndrome. Results found that this hyperinflammatory syndrome presented with dermatologic, mucocutaneous, and gastrointestinal manifestations and was associated with cardiac dysfunction.
Verdoni et al.
In Bergamo province, Italy, an outbreak of Kawasaki disease was diagnosed during the COVID-19 epidemic centered there. The incidence, features, and treatment of patients with such Kawasaki-like disease are detailed in this study.
Chiotos et al.
This study looks at 6 critically ill children with Multisystem Inflammatory Syndrome in Children (MIS-C). The patients received therapies that have been used successfully for the treatment of Kawasaki disease, including IVIg and methylprednisolone. In most patients, this was highly effective in reducing systemic inflammation, as evidenced by resolution of fever, with improving cardiac function over a period of days. Overall, five of the six patients described in this cohort have been discharged from the hospital.